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Abstract: Down syndrome (DS) is the most common genetic cause of intellectual disability that is 
associated with an increased risk to develop early-onset Alzheimer-like dementia (AD). The brain 
neuropathological features include alteration of redox homeostasis, mitochondrial deficits, 
inflammation, accumulation of both amyloid beta-peptide oligomers and senile plaques, as well as 
aggregated hyperphosphorylated tau protein-containing neurofibrillary tangles, among others. It is 
worth mentioning that some of the triplicated genes encoded are likely to cause increased oxidative 
stress (OS) conditions that are also associated with reduced cellular responses. Published studies 
from our laboratories propose that increased oxidative damage occurs early in life in DS population 
and contributes to age-dependent neurodegeneration. This is the result of damaged, oxidized 
proteins that belong to degradative systems, antioxidant defense system, neuronal trafficking. and 
energy metabolism. This review focuses on a key element that regulates redox homeostasis, the 
transcription factor Nrf2, which is negatively regulated by BACH1, encoded on chromosome 21. 
The role of the Nrf2/BACH1 axis in DS is under investigation, and the effects of triplicated BACH1 
on the transcriptional regulation of Nrf2 are still unknown. In this review, we discuss the 
physiological relevance of BACH1/Nrf2 signaling in the brain and how the dysfunction of this 
system affects the redox homeostasis in DS neurons and how this axis may contribute to the 
transition of DS into DS with AD neuropathology and dementia. Further, some of the evidence 
collected in AD regarding the potential contribution of BACH1 to neurodegeneration in DS are also 
discussed. 
Keywords: oxidative stress; BACH1; Nrf2; Down syndrome; Alzheimer disease 
 
1. Genetics of Oxidative Stress in Down Syndrome 
Down syndrome (DS) or trisomy 21 is one of the most common genetic disorder displaying 
phenotypic features that include neurodevelopmental defects, neuronal dysfunction, and accelerated 
aging, among others Cenini, Dowling [1], [2,3]. Further, DS individuals are at increased risk to 
develop a type of dementia that mimics the clinical and pathological features course of Alzheimer 
disease (AD), with the deposition of amyloid plaques and neurofibrillary tangles. Interestingly, DS is 
emerging as a disorder etiologically related to oxidative stress (OS) mainly due to triplication of Cu, 
Zn-superoxide dismutase (SOD-1), encoded on chromosome 21 (Hsa21). However, recent reports 
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showed that OS is driven not only from overexpression of some Hsa21 genes, but also from a 
dysregulation of gene/protein expression associated with the trisomy [4]. 
OS results from either elevated production of reactive oxygen and nitrogen species (ROS/RNS) 
or by reduced antioxidant responses. The central nervous system (CNS) contains high levels of fatty 
acids that in the presence of high metabolic flux are a fertile ground for lipid peroxidation reactions 
responsible of generating increasing amount of free radicals as well as highly reactive products, such 
as 4-hydroxynonenal (HNE) [5–8]. In addition, superoxide anion (O2−•), hydrogen peroxide (H2O2), 
and hydroxyl radical (HO•), are continuously produced as by-products of aerobic respiration and 
various other catabolic/anabolic processes [9]. As a result, neuronal cells are highly susceptible to 
redox imbalance and to accumulate oxidative damage [10]. 
As an essential link to OS, mitochondrial dysfunction occurs whenever redox imbalances 
overcome the intracellular defense system, due to the main role of mitochondrial activity in oxygen 
metabolism and ROS production [11]. By-products of normal mitochondrial metabolism and 
homeostasis include the build-up of potentially damaging levels of ROS. A major source of free 
radicals is the mitochondrial oxidative phosphorylation pathway (OXOPHOS), in which electron 
leakage causes the formation of O2−• that, in turn, is converted by mitochondrial resident manganese 
superoxide dismutase (MnSOD) into H2O2 and O2 [12,13]. In line with this evidence, dysfunction of 
complex I has been found to be involved in the overproduction of ROS in skin fibroblast from DS, 
isolated from both fetal and adult subjects [14]. 
Accumulating studies implicate OS in DS pathological phenotypes [15–17], though the exact 
mechanisms through which oxidative damage translate into clinical features of DS need to be 
clarified. It is likely that OS is a chronic condition in DS brain, that initiates already during embryonic 
development and further accumulates with aging, representing a strong risk factor for subsequent 
neurodegeneration [18,19]. 
In order to better understand and appreciate the causes of OS in DS brain, initial explanations 
can be obtained by mapping the Hsa21 on which a number of genes (Table 1) such as SOD1, amyloid 
precursor protein (APP), the transcription factor BTB and CNC homology 1 (BACH1), the Protein C-
ets-2 (ETS2), carbonyl reductase (CBR), S100 calcium-binding protein B (S100B), among others, are 
directly involved in the overproduction of ROS as found in DS individuals and in mouse models 
thereof [20]. 
Table 1. List of some genes located on Hsa21 linked to OS, as discussed in the text. 
Gene on 
Hsa21 
Molecular 
Function 
Biological Process Relevance in Down Syndrome 
SOD-1 
(Cu,Zn-
superoxide 
dismutase 1) 
 
Oxidoreductase 
Antioxidant 
Response 
Triplication of SOD-1 in DS brain results in an imbalance 
in the ratio of SOD-1 to CAT and GPX (two enzymes 
involved in its metabolism), thus leading to the 
accumulation of H2O2 in the cells. 
 
APP (amyloid 
precursor 
protein) 
 
Heparin-binding, 
Protease inhibitor 
Apoptosis, Cell 
adhesion, 
Endocytosis, Notch 
signaling pathway 
and Aβ processing 
Triplication of APP causes the over-production of Aβ (1-
40/42) in DS brain. Deposition of senile plaques of Aβ is 
observed in post-mortem brain and plasma from DS 
compared with non-DS individuals. 
 
BACH1 (BTB 
Domain and 
CNC Homolog 
1) 
 
DNA-binding, 
Transcription 
regulation 
Antioxidant 
Response 
Triplication of BACH1, as a negative transcription 
regulator, in DS brain could block the induction of 
antioxidant genes, therefore promoting increased OS in 
the cell. 
CBR 
(Carbonyl 
reductase) 
 
Oxidoreductase 
Oxidative stress 
Response 
Triplication of CBR in DS play a role in exacerbating OS. 
Carbonyls are toxic metabolic intermediates that are 
mainly detoxified by aldehyde dehydrogenase or reduced 
by CBR and/or alcohol dehydrogenase to their 
corresponding alcohols. Increased levels of these enzymes 
were detected in the brain of DS patients, likely in 
response to elevated carbonyls production in DS. 
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ETS2 (Protein 
C-ets-2) 
 
Transcription 
regulation 
Cell differentiation, 
maturation and 
signaling 
Triplication of Ets-2 could play a role in the increased 
susceptibility of DS cells to undergo apoptosis given 
common pathophysiological features shared between Ets-
2 overexpressing transgenic mice and individuals with 
DS. 
S100B (S100 
calcium-
binding protein 
B) 
Ca2+-binding 
protein 
Neurotrophic factor 
Triplication of S100β in DS corresponds to an increase of 
its expression levels in astrocytes in association with 
neuritic plaques. In addition, chronic overexpression of 
S100β contributes to increased neuronal and neuritic 
βAPP expression with consequent accelerated amyloid 
deposition, as well as abnormal growth of neurites in β-
amyloid plaques, similar to observations in middle-aged 
DS patients. 
Among trisomic genes, SOD1 is one of the first lines of antioxidant defense by catalyzing the 
conversion of O2•− to molecular oxygen (O2) and H2O2, which can be neutralized by catalase (CAT) 
and by glutathione peroxidase (GPX) to water [21]. Moreover, the triplication of Hsa21 is not 
accompanied by a parallel increase of CAT and GPX, resulting in imbalance in SOD1/CAT levels and 
those of SOD1/GPX, with an accumulation of H2O2 [22]. Interestingly, in all DS tissues an altered 
SOD-1/GPX activity ratio has been observed [5], that may partially explain higher levels of H2O2 and 
its by-products. In addition to CAT and GPX, a decreased expression of peroxiredoxin 2 also was 
detected in DS fetal brain, which further contribute to the increased susceptibility of DS neurons to 
undergo oxidative damage [23]. 
Intriguingly, aberrant expression of SOD seems to be associated with mitochondrial impairment. 
Indeed, transgenic mice overexpressing wild-type human SOD1 (Tg-SOD1) show many 
mitochondrial defects such as increased mitochondrial swelling and vacuolization, that also are 
associated with learning and memory disturbance [7]. In addition, Tg-SOD1 mice have altered levels 
of ATP synthase alpha/beta chain and elongation factor Tu, while no changes in the levels of 
antioxidant proteins were observed [7]. Taken together, these alterations correlate with synaptosomal 
damage and neuronal loss in the brain of Tg-SOD1, ultimately leading to cognitive deficits in DS. 
Several studies reported that defects of mitochondrial structure and function are associated with 
increased ROS production [24–27]. In line with this assumption, mitochondrial dysfunction is 
considered a pathological signature of DS, also in the presence of increased OS condition [25]. 
Neurons of DS patients exhibited a significant increase in intracellular ROS levels together with 
elevated lipid peroxidation [5,26,27]. The DS mitochondrial phenotype includes: (i) reduced ability 
to produce ATP through OXPHOS; (ii) decreased respiratory capacity; and (iii) disruption of 
mitochondrial membrane potential, all events associated with loss of mitochondrial dynamics. These 
mitochondrial defects are present in all DS cell types, from peripheral tissues to the brain [28]. 
In addition to the well-recognized role of SOD1, increased OS could also be caused by the over-
production of Aβ, due to triplication of APP. This hypothesis is confirmed by a number of reports 
demonstrating that both Aβ (1-40/42) are able to induce OS, as in the case of AD [8,29]. Indeed, 
Butterfield and others [8,16,30,31] proposed that Aβ (1-42), in the form of oligomers, is able to insert 
into the membranes initiating lipid peroxidation and downstream cascades [29]. Accordingly, the 
levels of both Aβ (1-42) and Aβ (1-40) in plasma are higher in DS compared with non-DS controls 
and deposition of senile plaques is observed in post-mortem brain from DS individuals [32,33], very 
early in life. Further, Aβ has the ability to coordinate metal ions—Zn2+, Cu2+ and Fe2+—and the 
alteration of metal homeostasis is known to regulate both production and defense against ROS and 
is also involved in the regulation of neuronal activity in the synapses and other biological functions 
in the brain. It is interesting to underlie that studies from Anandatheerthavarada et al. [34] for the 
first time provided evidence that full length APP itself is able to damage mitochondria. Consistent 
with their work, mice overexpressing wild type human APP show cognitive defects and neuronal 
pathology similar to what observed in AD models, though these mice do not show significant Aβ 
deposition in the hippocampus [35]. These findings support the notion that, in addition to effects 
from APP-generated Aβ oligomers on mitochondria, trisomy of APP itself may promote 
mitochondrial dysfunction in DS. 
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BACH1, encoded on Hsa21, is a key element in the regulation of the antioxidant response in DS 
[6]. BACH1 is a transcription repressor that acts as a key regulator of the expression of genes involved 
in the cell stress response [36]. In DS, it is likely that upregulation of BACH1 protein levels could 
block the induction of antioxidant genes, therefore promoting increased OS in the cell [6]. The 
molecular aspects of BACH1 triplication will be discussed in the next section. 
By mapping Hsa21, another candidate gene that is related to OS is the enzyme carbonyl 
reductase (CBR). CBRs are NADPH-dependent cytosolic enzymes with broad substrate specificity for 
many endogenous and xenobiotic carbonyl compounds. They catalyze the reduction of endogenous 
prostaglandins, steroids, and other aliphatic aldehydes and ketones. Carbonyls are considered toxic 
metabolic intermediates, that can be detoxified both through oxidation by aldehyde dehydrogenase 
(ALDH) or by CBR-mediated reduction and/or alcohol dehydrogenase (ADH). Increased levels of 
both these enzymes were detected in the brain of both DS and AD patients, likely in response to 
elevated carbonyls production [37]. 
Published studies from our laboratories identified several oxidatively modified proteins in DS 
brain, prior and after development of AD [5,38,39]. Among several targets, oxidation of proteins 
could be particularly deleterious in aging and in age-related neurodegenerative diseases, due to a 
gradual loss of efficiency of clearance systems for their removal [37]. The role of OS in the 
development and progression of AD in the general population has been extensively discussed in 
several review papers [8,40,41]. Among the proteins identified by redox proteomics to be oxidatively 
modified, either by increased carbonylation or HNE modification, proteins involved in several 
intracellular processes such as (i) neuronal trafficking; (ii) the proteostasis network; (iii) energy 
metabolism; and (iv) mitochondrial function were found [6]. 
Reduced ATP levels, increased ROS, and altered mitochondrial permeability are characteristic 
mitochondrial defects of degenerating neurons not only in DS but also in many neurodegenerative 
disorders, including AD [8]. Overall, proteomics data demonstrate that oxidative damage is an early 
event in DS, and the dysfunction of protein clearance systems contributes to increased neuronal 
vulnerability to oxidative damage that accelerate neurodegenerative phenomena. As noted, 
considering that several of the above-mentioned proteins have been already found to be oxidized in 
AD brain, our results strongly support the notion that aberrant protein oxidation in DS may 
contribute to age-dependent AD risk. 
This view is also confirmed by a longitudinal study analyzing some redox markers in plasma 
samples from DS subjects (1–57 years old) showing that changes in redox-related parameters are 
strongly age-dependent [17]. Similarly, Pallardo and colleagues showed a significant increase in 8-
hydroxy-2-deoxyguanisine (8-OHdG) levels in DS patients up to 30 years old. Levels of antioxidants 
including ascorbic acid and vitamin E also were evaluated, showing that plasma concentrations of 
ascorbic acid are increased in young (<15 years) DS individuals, but not in older persons, while the 
levels of vitamin E did not differ from control either in young or older DS individuals compared with 
non-DS healthy individuals [17]. 
The picture that emerges from both brain and peripheral studies suggest that young DS 
individuals are characterized by an early pro-oxidant state [27] that results in a variety of pathological 
phenotypes. With age, adult DS persons accumulate oxidative damage associated with an increased 
risk to develop Alzheimer-like dementia [20,22]. Understanding the complexity of factors regulating 
redox homeostasis may help to identify potential therapeutic treatments able to prevent the 
accumulation of oxidative damage. In this scenario, it is particularly interesting to discuss the role 
played by BACH1/Nrf2 axis in DS. 
2. BACH1/Nrf2 Signaling 
Based on the considerations above, it is conceivable that OS occurs in DS pathogenesis and 
progression due to a dysregulation of gene/protein expression associated with the trisomy. As noted 
above, OS represents an imbalance between the production of ROS and the ability of a biological 
system to detoxify the reactive toxic intermediates—the antioxidant response—or to repair the 
resulting damage. 
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A prominent sensor involved in the antioxidant response is the Keap1-Nrf2-ARE (Kelch-like 
ECH-Associating protein 1- nuclear factor erythroid related factor 2-antioxidant response element) 
signaling complex. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) mediates 
induction of multiple antioxidant enzymes through activation of ARE of DNA. Activation of Nrf2 
results in cellular protection by increasing the expression of antioxidant enzymes such as NADPH 
quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1), and multiple components of the 
glutathione pathway. Promotion of this production of antioxidants is therefore a promising 
mechanism to protect against neurodegeneration. Under normal OS conditions, Keap1, a cysteine-
rich protein that senses redox changes in the cell, binds to Nrf2 leading to retention of Nrf2 in the 
cytosol and causing its proteasomal degradation [42,43]. Under OS, conformational changes in Keap1 
lead to its dissociation from the Nrf2-Keap1 complex and to the translocation of free Nrf2 into the 
nucleus, where it binds to ARE regions in the genome, to activate the expression of stress response 
genes [44]. So far, there is no complete information on Nrf2/Keap1 genes, protein levels or activities 
in DS. However, a recent study comparing gene expression profiles in DS and euploid astrocytes 
found that Nrf-2-associated oxidative stress response genes were differentially regulated in DS [45]. 
In addition, a study from Swatton et al. in DS reported that mitogen-activated protein kinases 
(MAPKs) are highly phosphorylate in DS and AD brains [46], and this result can be linked to the 
mechanism whereby MAPKs phosphorylate Nrf2 enabling its dissociation from the Nrf2/Keap1 
complex, but preventing its translocation into the nucleus. 
Compared to Nrf2, ARE transcriptional repressors and their roles in DS, AD, and other 
neurodegenerative disorders have been minimally investigated. Indeed, a novel hypothesis regards 
the implication of BACH1 to compete with the Keap1-Nrf2-ARE signaling complex. BACH1 is a 
member of the Cap “n.” Collar and basic region leucine zipper family (CNC-bZip) of transcription 
factors is encoded on HSA21 and functions primarily as a transcriptional repressor. Human BACH1 
is composed by 736 amino acids: (a) N-terminal region of BACH1 contains a BTB/POZ domain, which 
functions as a protein interaction motif; (b) while the C-terminal bZip domain binds to DNA forming 
heterodimers with small Maf proteins (i.e., MafK, MafF, and MafG) [47]. Once into the nucleus, 
BACH1-Maf heterodimers are able to inhibit the transcription of many oxidative stress-response 
genes. In addition, BACH1 contains six cysteine-proline (CP) motifs, four of which are located in a 
heme-binding region near the C- terminus. Heme is able to inactivate BACH1 by interacting with two 
of the CP motifs, leading to the exclusion of BACH1 from the nucleus [48]. Under pro-oxidant 
condition, nuclear BACH1 binds heme, changes its conformation, dissociates from ARE and allows 
transcription factors to bind and activate the expression of oxidative stress-responsive genes [49]. 
The export of BACH1 from the nucleus is also the result of its tyrosine phosphorylation, 
activated by the antioxidant response, (BACH1 tyrosine 486) [50] and by cadmium, which induces a 
cytoplasmic localization signal in the BACH1 C-terminus [51]. After its release in the cytoplasm, 
BACH1 forms fiber-like structures on microtubules in the presence of intracellular hyaluronic acid-
binding protein (IHABP), which regulates the subcellular localization of the former [51]. 
Many of the genes targeted by BACH1 are in common with the genes regulated by Nfr2 and 
participate in redox regulation, including HO-1, that is crucial for cell survival upon detrimental 
oxidative stress conditions. HO-1 expression is negatively regulated by BACH1 when heme levels 
are reduced, though higher heme levels are able to inhibit BACH1-DNA interaction and also promote 
BACH1 nuclear export and its subsequent degradation [52]. This event induces HO-1 expression, 
which in turn degrades heme while releasing antioxidant molecules such as carbon monoxide (CO), 
and biliverdin. Thus, the BACH1/HO-1 pathway is considered to act as a feedback loop that regulates 
heme homeostasis during sustained oxidative stress. 
Taken together, BACH1 is believed to displace Nrf2 from AREs [49] and to act primarily as a 
transcriptional repressor for antioxidant genes, such as HO-1 [53] and NQO1 [54]. Specifically, 
BACH1 competes with Nrf2 for binding to the AREs in oxidative stress-response genes. In response 
to OS, Nrf2 dissociates from Keap1, translocates into the nucleus, and binds to AREs as a heterodimer 
with Mafs, thereby activating oxidative stress-response genes as previously described, while BACH1 
is displaced from AREs and exported out of the nucleus [49] (Figure 1). A recent study suggests that 
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both the nuclear import of Nrf2 and the dissociation of BACH1-ARE are promoted by sirtuin-6 (Sirt 
6) [55]. Research from Dhakshinamoorthy et al. demonstrated that positive and negative regulation 
of ARE-mediated gene expression depend on the critical balance between Nrf2 and BACH1 in the 
nucleus. This was clearly evident from the observation that BACH1 repression of ARE-mediated gene 
expression was relieved by co-expression of Nrf2 with BACH1, and BACH1 failed to repress the ARE 
in cells overexpressing Nrf2. However, BACH1 repressed the ARE activation in cells expressing 
moderate levels of Nrf2 [54]. 
 
Figure 1. BACH1/Nrf2 signaling regulates antioxidant response. Under normal conditions (left), 
Keap1/Nrf2 retains Nrf2 in the cytoplasm. Exposure of cells to oxidative insult leads to the release of 
Nrf2 from Keap1/Nrf2. Nrf2 then translocates to the nucleus and binds to MAREs as a heterodimer 
with small Mafs, thereby activating oxidative stress-response genes (e.g., HO-1 and NQO1), while 
Bach1 is displaced from MAREs and exported out of the nucleus. In trisomic cells (DS) (right), 
triplication of BACH1 competes with Nrf2 thus resulting in reduced binding of Nrf2 to MAREs. This 
event may explain the increased oxidative stress levels of DS individuals, that is likely the result of 
compromised induction of antioxidant response. 
In light on these findings, focusing on DS individuals, the triplication of genes (e.g., BACH1) 
encoded on HSA21 is directly involved in the appearance of harmful conditions such as increased 
OS, which we hypothesize over time contributes to the early development of AD pathology in DS 
individuals. The presence of BACH1 on HSA21 opens the possibility of seeking new therapies 
capable of controlling the possible imbalance between Nrf2 and BACH1 in the nucleus. 
3. Involvement of BACH1 in AD and DS 
The evaluation of BACH1 functions in the brain and particularly in neurodegenerative disorders 
characterized by a failure of antioxidant responses, represents a novel aspect of DS research. Indeed, 
only a limited number of studies addressed this topic to date. 
Studies performed in BACH1 knock-out mice (BACH1−/−) showed significantly higher HO-1 
mRNA expression levels with respect to control animals in all brain regions studied [56]. Moreover, 
higher induction of HO-1 was observed around damaged tissues in BACH1−/− mice [56]. Similar 
results were collected with regard to spinal cord where HO-1 protein levels were found significantly 
higher in BACH1−/− than WT mice either before or after injury [57]. Furthermore, neuronal loss and 
apoptotic cell death in the injured spinal cord was significantly reduced in BACH1−/−mice [57]. Thus, 
as described above, these results confirm that BACH1 plays an important role in regulating HO-1 
expression levels in the central nervous system.  
The first evidence about a possible involvement of BACH1 in brain disorders came in 2003 when 
Shim et al. evaluated levels of BACH1 protein levels in a small cohort of post-mortem frontal cortex 
Antioxidants 2020, 9, 779 7 of 14 
samples collected from DS, AD, and related control individuals  to test the hypothesis that DS-
phenotype may be due to the overexpression of genes encoded on chromosome 21 [58]. Despite the 
prevalent hypothesis of a gene-dosage effect in DS, these authors found that BACH1 protein levels 
were significantly reduced in DS samples, suggesting that DS features cannot be simply explained by 
the overexpression of triplicated genes [58]. However, these findings were revised by the same group 
published in a subsequent study [59]. In the afore-mentioned work, fetal cortical specimens from DS 
fetuses and controls (females) from the 18-19th week of gestation were used to evaluate BACH1 
protein levels and levels of one of the targets of BACH1 activity, i.e., HO-1, among the others [59]. 
BACH1 was significantly overexpressed in fetal DS as compared to controls [59], while the levels of 
HO-1 were found comparable between the two groups [59]. In light of these results these researchers 
concluded that increased BACH1 did not lead to decreased HO-1, which would have explained 
oxidative stress observed in fetal DS [59]. 
However, we suggest that the above conclusion could be criticized. Considering that  HO-1 is 
inducible, with lower intracellular levels under physiological conditions, HO-1 levels are 
dynamically responsive to a variety of oxidative and inflammatory stimuli such as heme, Aβ, H2O2, 
heavy metals, UV light, hyperoxia, prostaglandins, nitric oxide (NO), peroxynitrite, 
lipopolysaccharide, oxidized lipid products and various growth factors [60–62]. Further, in the adult 
brain, HO-1 expression in basal conditions is restricted to sparse clusters of neurons and glia [60]. 
While in the unstressed rodent brain, low-level of HO-1 is observed in scattered neurons of the 
cerebral cortex, hippocampal dentate gyrus, thalamus, hypothalamus, and cerebellum [63–67]. 
Hence, reduced HO1 levels in DS frontal cortex might not be expected. The reason could simply be 
that increased BACH1 levels would prevent HO1 overexpression, which remains at similar levels to 
those observed in the control group. If considered in this way, no changes observed for HO-1 levels 
would lead to increased oxidative stress levels in DS brain, since HO-1 is among the first proteins 
induced to elicit an antioxidant response under conditions of increased oxidative stress levels [68–
70]. 
This hypothesis was further strengthened by proposing a role for BACH1 overexpression as one 
of the causes driving the development of neurodegeneration in DS [6]. Indeed, the expression levels 
and the ubiquitinylation of BACH1 were evaluated in post-mortem frontal cortical samples isolated 
from postmortem DS persons before and after (DSAD) the development of AD neuropathology, 
compared to age-matched controls [6]. Moreover, the incident effects of BACH1 on HO-1 and on its 
physiological partner biliverdin reductase-A (BVR-A)—both involved in the production of the 
antioxidant molecule bilirubin [60,61]—as well as the levels of NQO1, were determined. Results from 
this study highlighted that BACH1 protein levels are significantly elevated in DS subjects, either 
before or after the development of AD [6]. Furthermore, the evaluation of BACH1 post-translational 
modifications revealed that BACH1 mono-ubiquitinylation levels were reduced only in DS, while 
increased levels of BACH1 poly-ubiquitinylation were observed only in DSAD subjects [6]. 
In parallel, it was observed that neither HO-1 or NQO1 protein levels (both regulated by BACH1, 
[53,54]) were  different between DS and age-matched controls, while they were significantly 
increased in brains from the DSAD group [6]. Observations collected from DS individuals are in 
agreement with those previously reported by the group of Lubec and co-workers [59]. Moreover, 
further studies contributed to extending the knowledge about the regulation of BACH1 in DS. 
Indeed, by taking into consideration that mono-ubiquitinylation is involved in modulating protein 
function, compartmentalization, and interactions, while polyubiquitinylation is a signal for protein 
degradation [71,72], collectively, the results suggest that more than the expression levels, the 
regulation of BACH1 activity/degradation plays a role in DS and contributes to the explanation of 
observed changes with regard to HO-1 [6]. Increased BACH1 protein levels along with reduced 
BACH1 mono-ubiquitinylation would be responsible for the lack of HO-1 or NQO1 increase observed 
in DS, while increased BACH1 poly-ubiquitinylation (degradation) would drive the observed 
increase of HO1 and NQO1 protein levels in DSAD persons [6]. Increased BACH1 poly-
ubiquitinylation could result from increased oxidative stress levels in DSAD individuals [6]. Similar 
analyses performed in a mouse model of DS, i.e., Ts65Dn mice, at different ages further suggest that 
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BACH1 overexpression results from the triplication of chromosome 21, although the mechanisms 
associated with BACH1 regulation appear different between mice and humans [6]. Indeed, the 
overexpression of BACH1 was not associated with differences in the ubiquitinylation profile between 
Ts65Dn and control mice [6]. Increased BACH1 levels in Ts65Dn mice tend to maintain HO-1 
expression levels comparable to those of euploid animals [6]. 
The pivotal role for BACH1 in the regulation of antioxidant response in DS is further highlighted 
by data collected with regard to BVR-A. As indicated above, BVR-A is normally co-expressed with 
HO-1 to promote the degradation of pro-oxidant heme into the antioxidant molecule bilirubin [61,73]. 
Notwithstanding that BVR-A possesses pleiotropic functions through which this enzyme regulates 
intracellular signaling [73]. Among these functions, Maines’ group identified BVR-A as a heme-
binding and heme transport protein, and suggested its role in the modulation of the expression of 
heme-regulated genes [74]. In particular, these researchers proposed that transport of heme to the 
nucleus by BVR-A would enable its delivery to the transcriptional repressor BACH1, which, on 
binding heme dissociates from the DNA, and is replaced by the Nrf2 transcription factor [74]. Indeed, 
cells lacking BVR-A were characterized by reduced HO-1 expression in response to heme [74]. 
Moreover, increased BVR-A levels were observed in both DS and DSAD individuals with respect to 
age-matched controls [6]. However, they were not associated with increased HO1, particularly in DS, 
further suggesting that over-expression of BACH1 precludes HO-1 upregulation mediated by 
physiological activators, including BVR-A. 
Studies about the possible involvement of BACH1 in AD neuropathology mostly rely with in 
vitro analyses. The only report aimed to evaluated levels of BACH1 in AD brain shows no changes 
with respect to control subjects [58]. This gap in knowledge about functions of BACH1 in AD needs 
to be fulfilled in future studies, particularly in light of the role for HO1 and reduced antioxidant 
response in the onset and progression of AD pathology [60,61,75]. While HO-1 and NQO1 protein 
proteins levels are elevated in AD brain (reviewed in [61,76]), reduced Nrf2 activity was reported in 
a number of studies performed on human and animal samples. Indeed, reduced Nrf2 nuclear 
expression in hippocampal samples from AD subjects were observed [77]. Similarly, a failure of Nrf2-
mediated processes in AD mouse models was reported [78–81]. Together, these observations spur 
the necessity for deeper investigations into a possible role for BACH1 in AD. 
A previous study showed that BACH1 also targets the gene for microtubule-associated protein 
tau (also known as MAPT)—known to drive AD progression [82]—by repressing its expression [83]. 
In this context, Koglsberger et al. reported that BACH1 expression contributes to molecular gender 
differences observed in tauopathies and AD and provides a new target for intervention strategies to 
modulate MAPT expression [84]. Since gender differences may influence the risk for brain disorders 
and the severity of their phenotypic manifestations, the role for BACH1 appears of great interest. 
Indeed, there is evidence of a gender difference in the phenotypic expression of AD in DS. Female 
middle-aged DS individuals have an earlier onset and a more severe form of AD that correlates with 
higher neocortical neurofibrillary tangles (NFT) rather than senile plaques (SP) density (2). 
Among the in vitro studies that assessed a role for BACH1 in neuronal injury, Piras et al. 
evaluated the effects of increased oxidative stress levels, mimicked by H2O2, in differentiated SH-
SY5Y cells [85]. A striking finding of this work is represented by the fact that in differentiated cells 
BACH1 is not displaced from the HO-1 promoter and Nrf2 is not allowed to bind, while maintaining 
its ability to sense H2O2 moving into the nucleus [85]. In addition, BACH1 and Nrf2 mRNA levels 
were not modified by increased oxidative stress levels, further corroborating the hypothesis that the 
main regulation of both BACH1 and Nrf2 occurs at the post-transcriptional level [85]. These results 
agree with findings from our group with regard to DS (cited above) and reinforce the hypothesis that 
the sole evaluation of protein and/or transcripts levels are not sufficient to unravel the molecular 
mechanisms regulated by BACH1 (Table 2). 
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Table 2. Summary of BACH-1 alterations observed in Down syndrome and Alzheimer disease. 
Pathology BACH1 Changes References 
Down 
Syndrome (DS) 
↑ BACH1 protein levels in fetal cortical 
specimens of human DS 
Ferrando-Miguel R.J. Neural Transm Suppl, 
2003(67): p. 193-205 Tili, E., et al., Ann Diagn 
Pathol, 2018. 34: p. 103-109. 
↑ BACH1 protein levels in human DS subjects, 
either before or after the development of AD 
Di Domenico, F., et al., J.Alzheimers Dis, 2015. 
44(4): p. 1107–20. 
Changes in post-translational modifications of 
BACH-1: 
Di Domenico, F., et al., J.Alzheimers Dis, 2015. 
44(4): p. 1107–20. 
↓ mono-ubiquitination of BACH1 in young DS 
human brain 
↑ poly-ubiquitinylation of BACH1 only in DSAD 
subjects 
↑ BACH1 protein levels in brain of Ts65Dn mice. 
Di Domenico, F., et al., J.Alzheimers Dis, 2015. 
44(4): p. 1107–20. 
No changes were observed in BACH1 
ubiquitination in Ts65Dn mice compared to 
euploid mice. 
Alzheimer 
Disease (AD) 
 
NO changes were observed in BACH1 protein 
levels in AD brain. 
Shim, K.S., R. Ferrando-Miguel, and G. Lubec, J 
Neural Transm Suppl, 2003(67): p. 39–49. 
↑ BACH1 protein levels in AD Brain using an 
immunohistochemistry approach. 
Tili, E., et al., Ann Diagn Pathol, 2018. 34: p. 103–
109. 
Finally, a role for specific micro RNAs (miRNAs) in regulating BACH1 expression was 
identified. miRNAs are key regulatory molecules, given their ability to disrupt expression of target 
mRNAs [86]. With the attempt to better clarify potential regulators of BACH1 in DS, Tili et al. 
evaluated the expression levels of miR155, which is one of the miRNA encoded on chromosome 21 
that also targets the BACH1 gene [87]. These scientists found that miR-155 is overexpressed only in 
DS brain, but not in control samples or even in AD samples took as reference [87]. Furthermore, these 
researchers found BACH 1 protein was strongly expressed in the DS fetal brain tissues, but not in 
adult DS with dementia with respect to controls [87]. Reduced BACH1 levels in DS with dementia 
with respect to AD samples were also observed [87]. miR-155/BACH1 levels strongly correlated with 
the disease process in DS [87]. The results from Tili et al. are apparently in contrast to the 
overexpression of BACH1 found by Di Domenico et al. [6]. However, there are two key points that 
deserve attention because they represent differences between the two studies. The number of DS 
samples (samples were collected from 3 DS donors in Tili et al. [87] vs. 8 samples in Di Domenico et 
al. [6]), and the age of the donors was different as well (34 to 42 in Tili et al. [87] vs. 59 in Di Domenico 
et al. [6]). Furthermore, in Tili et al. AD samples were not matched for age with Control or DS, were 
used [87]. Hence, in our opinion, the conclusions about the strong association between miR-
155/BACH1 and the development of dementia in DS require more extensive investigation. 
Another miRNA identified through a bioinformatic analysis as a potential regulator of BACH1 
is miR-98-5p [88]. miR-98-5p is a stress-related miRNA that plays an important role in regulating cell 
survival, apoptosis, and oxidative stress in multiple cell types and diseases [88]. Sun et al. reported 
that miR-98-5p alleviates neuronal injury induced by oxygen-glucose deprivation/reoxygenation, by 
also reducing reactive oxygen species levels [88]. Indeed, overexpression of miR-98-5p significantly 
suppressed the expression of BACH1 at the mRNA and protein levels, while inhibition of this micro 
RNA promoted the expression of BACH1 [88]. miR-98-5p overexpression also significantly increased 
the nuclear translocation of Nrf2 and promoted the activity of ARE [88]. As a consequence, the 
transcription of NQO1 and HO-1 also were significantly upregulated [88]. The role of miR-98-5p was 
confirmed by showing that BACH1 overexpression reversed the neuroprotective effects mediated by 
miR-98-5p overexpression [88]. These findings suggest a neuroprotective role for miR-98-5p by 
affecting the oxidative stress response through BACH1 suppression. 
4. Concluding Remarks 
Collected evidence suggests that young DS individuals are characterized by an early pro-oxidant 
state that contributes to a variety of pathological phenotypes. Among the genetic elements involved 
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in the regulation of redox homeostasis, triplication of SOD1 and BACH1, are considered to play a 
major role. Since SOD1 is directly responsible for production of hydrogen peroxide, triplication of 
BACH1 has wider effects because of its role in the BACH1/Nrf2 axis-induced antioxidant response. 
Considering that with age adult DS individuals accumulate oxidative damage in brain associated 
with an increased risk to develop Alzheimer-like dementia, modulation of the BACH1/Nrf2 axis in 
DS may represent a promising therapeutic strategy. Further studies are needed to dissect the 
complexity of targets that are controlled by BACH1/Nrf2 signaling and the potential mechanisms 
that are relevant to aging and neurodegeneration not only in DS but also in AD and, potentially, in 
other neurodegenerative disorders. 
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AD Alzheimer disease 
APP amyloid precursor protein 
ARE antioxidant response element 
BACH1 the transcription factor BTB and CNC homology 1 
BVR-A biliverdin reductase A 
CAT catalase 
CBR carbonyl reductase 
CO carbon monoxide 
DS Down syndrome 
DSAD Down syndrome with Alzheimer disease 
ETS2 the Protein C-ets-2 
HNE 4-hydroxy-2-nonenal 
HO-1 heme oxygenase 1 
HSA21 human chromosome 21 
Keap1 Kelch-like ECH-Associating protein 1 
MAPK mitogen-activated protein kinase 
MAPT microtubule associated protein tau 
NFT neurofibrillary tangles 
NO nitric oxide 
NQO1 NADPH quinone oxidoreductase 1 
Nrf2 nuclear factor erythroid 2 related factor 2 
OXOPHOS oxidative phosphorylation 
OS oxidative stress 
ROS reactive oxygen species 
SOD1 Cu, Zn superoxide dismutase 1 
MnSOD manganese superoxide dismutase 
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